Activated thrombin-activable fibrinolysis inhibitor (TAFIa) is a carboxypeptidase B that can down-regulate fibrinolysis. TAFIa is a labile enzyme that can be inactivated by conformational instability or proteolysis. TAFI is ϳ40% identical to pancreatic carboxypeptidase B (CPB). In contrast to TAFIa, pancreatic CPB is a stable protease. We hypothesized that regions or residues that are not conserved in TAFIa compared with pancreatic CPB play a role in the conformational instability of TAFIa and that replacement of these non-conserved residues with residues of pancreatic CPB would lead to a TAFIa molecule with an increased stability. Therefore, we have expressed, purified, and characterized two TAFI-CPB chimeras: TAFI-CPB-(293-333) and TAFI-CPB-(293-401). TAFI-CPB-(293-333) could be activated by thrombin-thrombomodulin, but not as efficiently as wild-type TAFI. After activation, this mutant was unstable and was hardly able to prolong clot lysis of TAFIdeficient plasma. Binding of TAFI-CPB-(293-333) to both plasminogen and fibrinogen was normal compared with wild-type TAFI. TAFI-CPB-(293-401) could be activated by thrombin-thrombomodulin, although at a lower rate compared with wild-type TAFI. The activated mutant displayed a markedly prolonged half-life of 1.5 h. Plasmin could both activate and inactivate this chimera. Interestingly, this chimera did not bind to plasminogen or fibrinogen. TAFI-CPB-(293-401) could prolong the clot lysis time in TAFI-deficient plasma, although not as efficiently as wild-type TAFI. In conclusion, by replacing a region in TAFI with the corresponding region in pancreatic CPB, we were able to generate a TAFIa form with a highly stable activity.
The coagulation system is a potent mechanism that prevents blood loss after vascular injury. It consists of a number of linked enzymatic reactions resulting in thrombin generation. Thrombin converts soluble fibrinogen into a fibrin clot. The central protein of the fibrinolytic system, plasmin, dissolves the blood clot by degrading the fibrin polymers into soluble fragments.
Thrombin-activable fibrinolysis inhibitor (TAFI) 1 (1, 2) , also known as plasma procarboxypeptidases B, R, and U, provides an important link between the coagulation and fibrinolytic systems (3) (4) (5) . Activated TAFI (TAFIa) down-regulates fibrinolysis, presumably by removing C-terminal lysines from fibrin that is already partially degraded by plasmin. Those lysines act as ligands for the lysine-binding sites of plasminogen and tissuetype plasminogen activator (t-PA). Removal of the lysines attenuates the fibrin cofactor function of t-PA-mediated plasminogen activation, resulting in prevention of accelerated plasmin formation and consequently down-regulation of fibrinolysis (6) .
TAFI is, in analogy to other carboxypeptidases such as pancreatic procarboxypeptidase B, proteolytically activated by thrombin or plasmin by cleavage at Arg 92 , which results in release of the activation peptide from the catalytic domain (7) . TAFIa is a labile enzyme, with a half-life of Ͻ10 min at 37°C (7) (8) (9) . TAFIa is inactivated by conformational instability, after which it becomes more susceptible to proteolytic degradation by thrombin (4, (7) (8) (9) (10) (11) . Plasmin can inactivate TAFIa by proteolysis of the catalytic domain (12) .
TAFI is classified as a member of the metallocarboxypeptidase subfamily. The pancreatic metallocarboxypeptidases playing a role in the digestive system are the best characterized members of this group. According to their substrate specificity, they are referred to as carboxypeptidase A, which preferentially hydrolyzes aliphatic C-terminal residues, or carboxypeptidase B (CPB), which, like TAFIa, preferentially hydrolyzes C-terminal basic amino residues. TAFI shows ϳ40% identity to pancreatic procarboxypeptidases; and upon activation, TAFI exerts CPB-like activity. Residues (7) . The presence of Asp 257 may determine the specificity for basic amino acids. TAFI is synthesized in the liver as a prepropeptide consisting of 423 amino acids (7) . The N-terminal signal peptide is removed upon secretion (7) .
Despite all the similarities between TAFI and pancreatic pro-CPB, pancreatic CPB is, in contrast to TAFIa, a stable protease (13) . We hypothesized that regions or residues that are not conserved in TAFI compared with pancreatic pro-CPB play a role in the conformational instability of TAFIa and that replacement of these non-conserved residues of TAFI with the corresponding ones of pancreatic CPB would lead to a TAFIa molecule with an increased stability. Several mutant forms of TAFIa with variations in the Arg 302 -Arg 330 region have an altered stability. Recently, a naturally occurring variation was found at position 325 (Thr 325 or Ile 325 ) in human TAFI (14, 15) . The isoleucine residue at position 325 extends the half-life of TAFIa from 8 to 15 min at 37°C. The Ile 325 variant also exhibits an increased antifibrinolytic potential of TAFIa compared with the Thr 325 variant (14, 15) . Interestingly, mutations at positions 302, 320, and 330 all have a negative effect on the stability of TAFIa, and the variation at position 325 lies between these residues (9) . Therefore, we expressed, purified, and analyzed two TAFI-CPB chimeric proteins in which parts of this C-terminal region of TAFI were replaced with the corresponding ones of pancreatic CPB.
EXPERIMENTAL PROCEDURES
Materials-Rabbit lung thrombomodulin and the sheep anti-TAFI polyclonal antibody were purchased from American Diagnostica, Inc. (Greenwich, CT). Hippuryl-Arg and H-D-Phe-Pro-Arg chloromethyl ketone (PPACK) were from Bachem (Bubendorf, Switzerland). Porcine pancreatic CPB was from Roche Applied Science (Almere, The Netherlands), and potato carboxypeptidase inhibitor was from Calbiochem. Thrombin was a generous gift from Dr. W. Kisiel (University of New Mexico, Albuquerque, NM), plasmin from Dr. A. Reijerkerk (University Medical Center, Utrecht, The Netherlands), and pancreatic pro-CPB cDNA from Drs. N. Dekker and M. Strömquist (AstraZeneca, Södertä lje, Sweden). t-PA was obtained from Chromogenix (Mölndal, Sweden). A peroxidase-conjugated rabbit anti-sheep antibody, a peroxidase-conjugated swine anti-mouse antibody, and a rabbit anti-fibrinogen antibody were all purchased from Dako Corp. (Glostrup, Denmark). Plasminogen and human fibrinogen free of von Willebrand factor and fibronectin were purchased from Enzyme Research Laboratories (South Bend, United Kingdom).
Cloning and Expression of Recombinant TAFI and TAFI-CPB Chimeras-The cloning of TAFI was described previously (10) . The cDNA of human pancreatic pro-CPB was used in a PCR to amplify the fragment encoding amino acids 288 -327 (pro-CPB numbering) using the forward primer GCA TGC ACT CGT ACT CCC AAA TGA TG and the reverse primer CCA TGG CCA TAT GTG TAC TTG GTG C, introducing an SphI and an NcoI cleavage site (underlined), respectively. The pancreatic CPB fragment encoding amino acids 288 -395 (C terminus) was amplified by PCR using the forward primer GCA TGC ACT CGT ACT CCC AAA TGA TG and the reverse primer GGT ACC TTA GTA CAG GTG TTC CAG GAC GTA G, introducing an SphI and a KpnI cleavage site (underlined), respectively. The PCRs (100 l) contained ϳ100 pmol of each primer, 250 M dNTPs, 2 ng of template DNA, and 5 units of Pwo polymerase. The PCR cycling conditions were as follows: 1 min at 95°C, 1 min at 55°C, and 2 min at 72°C for 25 cycles. The PCR products were cloned into TOPO ZeroBlunt (Invitrogen) according to the manufacturer's recommendations. The fragments were digested with SphI and NcoI (CPB-(288 -327)) or SphI and KpnI (CPB-(288 -395)) out of the respective TOPO vectors and ligated into pfastBacTAFI. This resulted in two chimeric constructs in which the base pairs encoding amino acids 293-333 and 293-401 of TAFI, respectively, were replaced with the base pairs encoding the corresponding amino acid residues of pancreatic CPB. The TAFI-CPB chimeras were excised from the vectors using XbaI and KpnI and ligated into the eukaryotic expression vector pcDNA3.1 (Invitrogen). Both constructs were confirmed by sequencing and were found to contain the Thr 147 isoform of TAFI. Our wild-type TAFI contained the Thr 147 and Thr 325 isoforms. The constructs were used to make stably transfected baby hamster kidney cells as described (16) . Stably expressing clones were cultured to confluency in a cell factory, and the medium was changed to UltraCHO (BioWhittaker, Inc., Walkersville, MD) and harvested twice a week. The recombinant chimeras were named TAFI-CPB-(293-333) and TAFI-CPB-(293-401).
Purification of TAFI and TAFI-CPB Chimeras-TAFI was purified essentially as described (10) . Briefly, culture media were applied to a PD-10 Sephadex G-25M column (Amersham Biosciences) coupled to a CNBr-activated Sepharose column to which an antibody against TAFI (monoclonal antibody Nik-9H10) was coupled. The columns were equilibrated in Tris-buffered saline (TBS; 50 mM Tris and 150 mM NaCl, pH 7.4). Unbound and nonspecifically bound proteins were washed away with 0.5 M NaCl in TBS, and bound protein was eluted with 0.1 M glycine, pH 2.7. The eluted fractions were collected in 1/10 (v/v) 1 M Tris, pH 9; pooled and diluted three times in H 2 O; and applied to a CNBractivated Sepharose column to which an antibody against human serum albumin was coupled. The flow-through was applied to a protein G-Sepharose column. Both columns were equilibrated with 20 mM Tris, pH 7.4. The flow-through was applied to a Mono Q column equilibrated with the same buffer. Bound protein was eluted with a linear gradient (0 -0.5 M NaCl in 20 mM Tris, pH 7.4). Samples were analyzed by silver-stained SDS-PAGE, and fractions containing a single band of ϳ60 kDa were pooled. Concentrations were determined with a BCA kit (Pierce) using bovine serum albumin as a standard.
TAFI Activation and TAFIa Activity Assay-The assay was basically carried out as described (17) . To follow the activation and inactivation of TAFI over time, TAFI, TAFI-CPB-(293-333), or TAFI-CPB-(293-401) (12.5 nM; all concentrations are final concentrations) was added to a premixture of thrombin (16 nM) and thrombomodulin (32 nM) or plasmin (100 nM), both in the presence of CaCl 2 (10 mM), in 20 mM Hepes, pH 8.0, and 0.1% bovine serum albumin. The mixtures were incubated at 37°C. To measure the rate of activation, 12.5 nM TAFI, TAFI-CPB-(293-333), or TAFI-CPB-(293-401), 8 nM thrombin, 16 nM thrombomodulin, and 5 mM CaCl 2 were used; and the mixtures were incubated at 4°C. At several time points, 20-l samples were withdrawn and added to 50 l of a mixture of PPACK (30 M) or aprotinin (25 g/ml) to stop thrombin or plasmin activity, respectively, and hippuryl-Arg (21.4 mM) as a substrate. After 30 min of incubation at 37°C, substrate conversion was stopped by addition of 50 l of 1 M HCl. Then, o-methylhippuric acid (22.5 M) was added as an internal standard, and both o-methylhippuric acid and hippuric acid were extracted using a solid-phase extraction unit (Waters Oasis, Wexford, Ireland) according to the supplier's recommendation, and samples were analyzed by high pressure liquid chromatography as described (17) . TAFIa activity is expressed in units/liter. One unit of enzyme activity is defined as the amount of enzyme required to hydrolyze 1 mol of substrate/min at 37°C under the conditions described (17) .
Clot Lysis Assay-The clot lysis assay was performed essentially as described previously (18) . Briefly, 70 l of citrated human TAFI-deficient plasma (TdP) (19) was mixed with various concentrations of TAFI, TAFI-CPB-(293-333), TAFI-CPB-(293-401), or porcine pancreatic CPB. The volumes were adjusted to 100 l with Hepes-buffered saline (HBS; (25 mM Hepes, 137 mM NaCl, and 3.5 mM KCl, pH 7.4) containing 0.1% bovine serum albumin. For some experiments, TAFI-CPB-(293-401) (1.7 M) was pre-activated by incubation with thrombin (17 nM), thrombomodulin-Sepharose (ϳ400 pmol of thrombomodulin/ml of Sepharose was coupled, and 20 l of a 1:4 slurry of beads/HBS was added to the reaction mixture, giving a final concentration of maximally 27 nM), and CaCl 2 (5 mM). The volume was adjusted to 60 l with HBS, and the sample was incubated at 37°C in a shaking incubator for 30 min. After incubation, the sample was centrifuged for 1 min, and various volumes of the supernatant were added in the lysis assay. To check if activation of TAFI-CPB-(293-401) had occurred, a sample was also measured in the activity assay described above. The activation mixture (thrombomodulin-Sepharose, thrombin, and CaCl 2 in HBS) without TAFI-CPB-(293-401) was used as a control. For the clot lysis assay, a mixture (50 l) of thrombin (final concentration in assay of 20 nM), CaCl 2 (final concentration in assay of 10 mM), and t-PA (final concentration in assay of 30 units/ml) was added to the plasma. The volume was adjusted to 150 l with HBS and 0.1% bovine serum albumin. The experiments were done in the presence or absence of 5 l of carboxypeptidase inhibitor (7.8 M). To determine the plasmin concentration required for clot lysis, fibrinogen (2 mg/ml) was mixed with thrombin (20 nM), CaCl 2 (10 mM), and various concentrations of plasmin (0 -200 nM), and the volume was adjusted to 150 l with HBS and 0.1% bovine serum albumin. For all experiments, samples (100 l) were transferred to a microtiter plate, and turbidity was measured over time at 37°C at 405 nm in a Thermomax microplate reader (Molecular Devices, Menlo Park, CA). The clot lysis time is defined as the time at which half-maximal lysis occurred.
Affinities of Anti-TAFI Antibodies for TAFI and TAFI-CPB Chimeras-TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) (3 g/ml)
were immobilized overnight at 4°C on a 96-well plate (Maxisorp, Nunc International). The wells were blocked by incubation with blocking buffer (TBS containing 3% bovine serum albumin; 200 l/well) at 37°C for 2 h. Samples of a sheep anti-TAFI polyclonal antibody or a mouse anti-TAFI monoclonal antibody (Nik-9H10) (0 -10 g/ml, 100 l/well) were allowed to bind to the immobilized proteins at room temperature for 1.5 h. After washing with TBS containing 0.1% Tween 20, the plates were incubated with a peroxidase-conjugated rabbit anti-sheep anti-body or a peroxidase-conjugated swine anti-mouse antibody, respectively, diluted 1:1000 in blocking buffer (100 l/well) at room temperature for 1 h. After a final washing step, peroxidase activity was detected with o-phenylenediamine (0.4 mg/ml) in phosphate/citrate buffer (100 mM Na 2 HPO 4 and 50 mM citric acid, pH 5.0) with 0.035% H 2 O 2 (100 l/well). Color was allowed to develop, after which the reaction was stopped by addition of 1 M sulfuric acid to each well (50 l/well), and absorbance was measured at 490 nm. The data were analyzed by fitting to the one-site binding equation:
, where B max is the maximal binding, and K D is the concentration of ligand required to reach half-maximal binding.
Fibrinogen Binding-Fibrinogen (1 g/ml in 50 mM Na 2 CO 3 / NaHCO 3 , pH 9.6; 100 l/well) was immobilized overnight at 4°C on a 96-well plate (Maxisorp). The wells were blocked by incubation with blocking buffer (200 l/well) at 37°C for 2 h. Samples of TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) (0 -1.7 M, 100 l/well) were allowed to bind to the immobilized fibrinogen at room temperature for 1.5 h. In a separate experiment, TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) (0 -167 nM) were incubated with thrombin (20 nM), thrombomodulin (5 nM), and CaCl 2 (5 mM) prior to binding to fibrinogen. The volume was adjusted to 180 l with TBS. At different time points, thrombin activity was stopped by addition of 60 l of PPACK (final concentration of 37.5 M). Samples (100 l/well, in duplicate) of these incubation mixtures were then allowed to bind to the immobilized fibrinogen. After washing with TBS containing 0.1% Tween 20, the plates were incubated with a sheep anti-TAFI polyclonal antibody (3 g/ml, 100 l/well) for 1 h at room temperature, washed again, and incubated with a peroxidase-conjugated rabbit anti-sheep antibody diluted 1:1000 in blocking buffer (100 l/well) at room temperature for 1 h. After a final washing step, peroxidase activity was detected with o-phenylenediamine (0.4 mg/ml) in phosphate/citrate buffer with 0.035% H 2 O 2 (100 l/well). Color was allowed to develop, after which the reaction was stopped by addition of 1 M sulfuric acid to each well (50 l/well), and absorbance was measured at 490 nm.
To investigate the binding of fibrinogen in solution to TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) that had been incubated previously with thrombin, thrombomodulin, and CaCl 2 as described above, fibrinogen (3 g/ml) was added to the pre-activated samples, and complex formation was allowed for 30 min at room temperature. Samples (100 l/well, in duplicate) were then transferred to a 96-well plate on which a rabbit anti-fibrinogen antibody (3 g/ml) had been immobilized, and the same procedure as described above was followed to detect binding. The data were analyzed (except for the binding of the TAFIa forms) by fitting to the one-site binding equation (see above).
Plasminogen Binding-Plasminogen was purified as described (20) . To study the binding of TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) to plasminogen, the same procedure as described for fibrinogen binding was used, with the following modifications. The wells were coated with plasminogen (3 g/ml). Samples of TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) (0 -333 nM, 100 l/well, at least in duplicate) were allowed to bind to the immobilized plasminogen, and binding was detected using mouse anti-TAFI monoclonal antibody Nik-9H10 (3 g/ml) and a peroxidase-conjugated rabbit anti-mouse secondary antibody diluted 1:1000 in blocking buffer. The data were analyzed by fitting to the one-site binding equation (see above).
Binding Studies Using a BIAcore 2000 Biosensor System-Plasminogen and fibrinogen were immobilized on a CM5 sensor chip using the amine coupling kit (BIAcore AB) according to the supplier's recommendation. Plasminogen and fibrinogen were applied in 10 mM NaAc, pH 3.1. Immobilization of plasminogen and fibrinogen on the chip resulted in increases in the resonance signal of ϳ1750 and ϳ2600 resonance units, respectively. Binding studies were done using 10 mM Hepes and 150 mM NaCl, pH 7.4, at a flow rate of 25 l/min at 25°C. The K D values were calculated using software provided with the instrument.
RESULTS
TAFI-CPB Chimeras-To determine regions that are important for the conformational instability of TAFIa, we constructed two TAFI-CPB chimeras, TAFI-CPB-(293-333) and TAFI-CPB-(293-401), in which amino acids 293-333 and 293-401, respectively, were replaced with the corresponding residues of pancreatic CPB (Fig. 1) . As a result, 28 of the 41 amino acids in sequence 293-333 were mutated in TAFI-CPB-(293-333) compared with wild-type TAFI, including the major thrombin cleavage site in TAFIa, Arg 302 , which is a Tyr residue in pancreatic CPB; and this chimera was 1 amino acid shorter than wild-type TAFI. TAFI-CPB-(293-401) contained another 31 extra amino acid changes in addition to the ones also present in TAFI-CPB-(293-333), again including the R302Y mutation, and included the same total number of amino acids as wild-type TAFI. In both chimeras, the polymorph residue 325 is a Ser residue. The constructs were stably expressed in baby hamster kidney cells, and the chimeric proteins were purified from culture media. The two chimeras were characterized and compared with recombinant human TAFI.
Activation of TAFI by the Thrombin-Thrombomodulin Complex-TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) were incubated with the thrombin-thrombomodulin complex at 37°C. At various time points, samples were removed; the reactions were stopped by addition of PPACK; and TAFIa activity was measured using hippuryl-Arg as a substrate. TAFI-CPB-(293-333) was activated by thrombin-thrombomodulin, but not as efficiently as wild-type TAFI. Under these conditions, the maximal TAFIa activity of TAFI and TAFI-CPB-(293-333) was reached by ϳ1 min, after which it decreased (Fig. 2A) . TAFI-CPB-(293-401) was activated at a lower rate than wild-type TAFI, and TAFIa-CPB-(293-401) was far more stable than wild-type TAFIa.
To study the rate of activation of TAFI and the TAFI-CPB chimeras in more detail, the system had to be modified to slow down the reaction by reducing the concentration of thrombin and thrombomodulin and by incubating the reaction mixtures at 4°C. The rates of activation of TAFI-CPB-(293-333) (8 Ϯ 1 units/liter s Ϫ1 ) and TAFI-CPB-(293-401) (0.3 Ϯ 0.1 units/liter s Ϫ1 ) were ϳ4 and ϳ100 times lower, respectively, than that of TAFI (32 Ϯ 7 units liter Ϫ1 s Ϫ1 ) (Fig. 2B) .
Stability of TAFIa, TAFIa-CPB-(293-333), and TAFIa-CPB-(293-401)-
To investigate the stability of the various TAFIa enzymes, TAFI and TAFI-CPB-(293-333) were activated for 1 min and TAFI-CPB-(293-401) for 10 min by the thrombinthrombomodulin complex, after which thrombin activity was or was not inhibited by addition of PPACK. In the absence of PPACK, both proteolytic and conformational inactivation could take place. In the presence of PPACK, proteolytic inactivation of TAFIa by thrombin was prevented, whereas spontaneous inactivation could still proceed. The samples were kept at 37°C to allow spontaneous conformational inactivation. The rate of TAFIa and TAFIa-CPB-(293-333) inactivation (Fig. 3A and Table I ) and TAFIa-CPB-(293-401) inactivation (Fig. 3B and Table I ) in the presence of PPACK did not differ from the rate of inactivation in the absence of PPACK (Fig. 3A and Table I ). The half-life of TAFIa-CPB-(293-333) (0.9 Ϯ 0.2 min) was reduced and that of TAFIa-CPB-(293-401) (96 Ϯ 29 min) was prolonged compared with wild-type TAFIa (2.9 Ϯ 0.2 min).
The thrombin-thrombomodulin complex cleaves TAFI (ϳ55 kDa) at Arg 92 , releasing the activation peptide (ϳ19 kDa; not visible on Coomassie Blue-stained SDS-polyacrylamide gels) from the catalytic domain (36 kDa). The catalytic domain is degraded further by cleavage at Arg 302 , resulting in fragments of 25 and 11 kDa. The major thrombin cleavage site (Arg 302 ), however, is mutated to a Tyr residue in both TAFI-CPB-(293-333) and TAFI-CPB-(293-401). SDS-PAGE analysis of samples of the activation mixtures revealed that the catalytic domains (36 kDa) of TAFI-CPB-(293-333) (Fig. 4A) and TAFI-CPB-(293-401) (Fig. 4B) were indeed not proteolyzed. This indicated that TAFIa-CPB-(293-333) and TAFIa-CPB-(293-401) could not be proteolytically inactivated by thrombin.
Functionality of TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) in a Plasma
System-The ability of TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) to protect a fibrin clot from lysis was studied in a clot lysis assay in which t-PA-mediated clot lysis of a thrombin-induced clot was fol-lowed spectrophotometrically over time. TdP was reconstituted with different concentrations of TAFI, TAFI-CPB-(293-333), or TAFI-CPB-(293-401) in either the absence or presence of a TAFIa-specific inhibitor, potato carboxypeptidase inhibitor (CPI). TAFI-CPB-(293-333) could hardly prolong the lysis time, whereas TAFI-CPB-(293-401) could prolong the lysis time in a concentration-dependent manner, although it was less efficient than wild-type TAFI and markedly less efficient than expected based on its half-life (Fig. 5A) . Addition of CPI completely inhibited the TAFI-or TAFI-CPB-(293-401)-dependent prolongation of the lysis time. Porcine pancreatic CPB prolonged the clot lysis time in a concentration-dependent way (Fig. 5B) .
Because the half-life of TAFIa-CPB-(293-401) was much longer than that of wild-type TAFIa, it was expected to protect the clot much better; but, in fact, higher concentrations of TAFI-CPB-(293-401) were needed to prolong the clot lysis time to a similar extent as wild-type TAFI. To investigate if the relatively low efficiency of TAFI-CPB-(293-401) in prolonging the lysis time of TdP was due to a low rate of activation by the thrombin-thrombomodulin complex, TAFI-CPB-(293-401) was activated before it was added to the clot lysis assay. TAFI-CPB-(293-401) was incubated with thrombin, thrombomodulinSepharose, and CaCl 2 at 37°C for 30 min. The thrombinthrombomodulin complex was then removed by centrifugation, and samples of the supernatant were added to the clot lysis assay. The activation mixture without TAFI-CPB-(293-401) treated in the same way had no effect on the clot lysis time. TAFIa-CPB-(293-401) was able to prolong the clot lysis time in a concentration-dependent manner slightly better than TAFI-CPB-(293-401) that had not been pre-activated; but, despite its long half-life, TAFIa-CPB-(293-401) was only marginally able to delay clot lysis (Fig. 5C) . Hence, it is likely that TAFIa-CPB-(293-401) was inactivated in this plasma environment by means other than intrinsic conformational instability or that it was less functional toward fibrin.
Activation of TAFI and Inactivation of TAFIa by PlasminOne of the possible explanations for the marginal potential of TAFI-CPB-(293-401) to attenuate fibrinolysis was that TAFI-CPB-(293-401) was inactivated by plasmin. In the past, plasmin was shown to be able to inactivate TAFIa by proteolysis. To estimate the amount of plasmin required for clot lysis, a clot lysis experiment with purified components was performed. Fibrinogen was clotted by addition of thrombin and CaCl 2 , and various concentrations of plasmin were included in the mixture to allow lysis. The lysis of the clots was followed by measuring the change in turbidity for 2 h (Fig. 6A) . At plasmin concentrations of 0, 10, and 25 nM, clots did not lyse completely within the 2-h timeframe. When 50 nM plasmin was used, the lysis time was ϳ0.5 h, which is about the lysis time of a clot of plasma in the presence of CPI or of TdP (compare Figs. 5A and   FIG. 1 . Comparison of the amino acid sequences of TAFI and human pancreatic CPB. Identical amino acids (:), amino acids thought to be important for substrate binding (*), the thrombin cleavage sites (2) , and the sequences of TAFI that were replaced with pancreatic CPB sequences in the two TAFI-CPB-(293-333) (light gray box) and TAFI-CPB-(293-401) (light and dark gray boxes) chimeras are indicated. 6A). Fifty nM plasmin is probably an underestimation of the plasmin concentration required for lysis of a plasma clot because, in the system with purified components, no ␣ 2 -antiplasmin or factor XIII was included. Therefore, TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) were incubated with 100 nM plasmin, and the activity was measured over time. Activation of TAFI-CPB-(293-333) by plasmin was very inefficient; hardly any activity could be measured (Fig. 6B) . Although plasmin could activate TAFI, the activation of TAFI-CPB-(293-401) was far more efficient. TAFI and TAFI-CPB-(293-401) reached maximal TAFIa activity approximately at the same time (by ϳ5 min), after which the activity decreased again. Furthermore, the activity of TAFIa-CPB-(293-401) was lost much faster in the presence of plasmin than after addition of the plasmin inhibitor aprotinin (Fig. 6B) , suggesting that plasmin is able to inactivate TAFIa-CPB-(293-401). Incubation of CPB (10 nM) with plasmin (0 -2 M) did not result in reduction of CPB activity (data not shown).
Previous research showed that plasmin cleaves TAFI at Arg 92 , resulting in release of the activation peptide from the 36-kDa fragment (7). The latter is cleaved further at several C-terminal sites, resulting in a polypeptide of 25-kDa and some smaller fragments. Some C-terminal cleavages can also occur prior to removal of the activation peptide, resulting in an ϳ44-kDa fragment that is no longer activable because it lacks critical amino acids involved in catalysis (12) . The plasmin cleavage patterns of TAFI and TAFI-CPB-(293-333) seemed similar to that of TAFI purified from plasma (12) as assessed by SDS-PAGE analysis (Fig. 6C) . The plasmin cleavage pattern of TAFI-CPB-(293-401) was, however, somewhat different (Fig.  6D) . The ϳ44-kDa fragment and most of the smaller fragments could not be observed, whereas more of the 36-kDa fragment 
TABLE I Half-lives of TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401)
The half-lives (mean Ϯ S.D.) of TAFIa, TAFIa-CPB-(293-333), and TAFIa-CPB-(293-401) were calculated from the data presented in Fig  3 . was visible. This is in agreement with the relatively high amount of activity measured when TAFI-CPB-(293-401) was incubated with plasmin ( Fig. 6B) . However, the exact plasmin cleavage site in TAFIa-CPB-(293-401) resulting in inactivation remains unclear.
Comparison of Fibrinogen and Plasminogen
Binding-To further characterize the chimeras, the binding to fibrinogen and plasminogen was studied. Fibrinogen or plasminogen was immobilized on a 96-well plate; several dilutions of TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) were applied to the plate; and bound TAFI was detected using a TAFIspecific antibody. TAFI and TAFI-CPB-(293-333) bound to the same extent to plasminogen (K D ϭ 26 Ϯ 5 and 25 Ϯ 5 nM, respectively) and fibrinogen (K D ϭ 943 Ϯ 383 and 239 Ϯ 29 nM, respectively), whereas the affinity of TAFI-CPB-(293-401) for both plasminogen and fibrinogen was severely reduced (Fig. 7,  A and B) . Similar results were obtained using a BIAcore biosensor system (Table II) -(293-401) . A, clot lysis times were determined in pooled normal plasma (NP) and TdP by measuring the turbidity of a thrombin-induced fibrin clot and t-PA-mediated fibrinolysis. The TdP was supplemented with various concentrations of TAFI, TAFI-CPB-(293-333), or TAFI-CPB-(293-401) as indicated. The experiments were done in the absence or presence (ϩ) of CPI to visualize the TAFIa-dependent prolongation of the clot lysis time. Each bar represents the mean Ϯ S.E. of two independent experiments. B, clot lysis times were determined in pooled normal plasma and TdP supplemented with various concentrations of porcine pancreatic CPB as indicated. C, to investigate if pre-activation of TAFI-CPB-(293-401) would ameliorate its antifibrinolytic potential, TAFI-CPB-(293-401) was incubated with thrombin-thrombomodulin-Sepharose at 37°C for 30 min. The activating complex was then spun down, and various volumes of the supernatant (containing activity as checked by the activity assay) were added to the TdP. The volumes of 4.5, 6.75, and 9 l correspond to 50, 75, and 100 nM (indicated in parentheses), respectively, as expressed in TAFI-CPB-(293-401) that was initially present in the pre-activation mixture. The same procedure was followed for thrombin-thrombomodulin-Sepharose, and the clot lysis times of various concentrations of TAFI-CPB-(293-401) that was not pre-activated are also included. The experiments were done in the absence or presence (ϩ) of CPI to visualize the TAFIa-dependent prolongation of the clot lysis time. Each bar represents the mean Ϯ S.E. of two independent experiments. thrombin activity was inhibited by addition of PPACK at different time points; and aliquots were taken and kept on ice to prevent further inactivation by conformational instability. The samples were then applied to immobilized fibrinogen, and bound TAFI was detected using a TAFI-specific antibody recognizing TAFI, TAFIa, and/or inactivated TAFIa (TAFIai) as well as the proteolytic fragments of 25 and 11 kDa. The binding of TAFI and TAFI-CPB-(293-333) increased upon longer incubation with the thrombin-thrombomodulin complex (Fig. 7C) . Binding is unlikely to depend on TAFIa activity because the activity time curve did not parallel the time course of binding (compare Figs. 2 and 7C) . However, proteolysis seemed to be required to increase the affinity of TAFI and/or TAFI fragments for fibrinogen. Binding of TAFI-CPB-(293-401) could not be induced by incubation with thrombin-thrombomodulin. To make sure that the absence of binding of TAFI-CPB-(293-401) to fibrinogen was not due to the immobilization process, the experiment was repeated; but this time, fibrinogen was added to the samples in solution, and binding was allowed for 30 min. Thereafter, formed complexes were captured by an immobilized antibody against fibrinogen. Binding was detected using a TAFI-specific polyclonal antibody. Also in this experimental setup, no binding of TAFI-CPB-(293-401) was observed.
To test if the differences in binding affinity of TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) for plasminogen and fibrinogen could be attributed to differences in affinity for the anti-TAFI antibodies used, we determined the affinities of the two antibodies for TAFI, TAFI-CPB-(293-333), and TAFI-CPB- A, in a purified system, the clot lysis times of thrombin-induced fibrin clots were determined in the presence of various concentrations of plasmin by measuring the change in turbidity. At 0, 10, and 25 nM plasmin, maximal lysis was not reached within the 2-h timeframe of the experiment (data are expressed as means Ϯ S.D., n ϭ 3). B, TAFI (f), TAFI-CPB-(293-333) (OE), and TAFI-CPB-(293-401) (q) were incubated with plasmin at 37°C. TAFI-CPB-(293-401) was also incubated with plasmin for 5 min at 37°C, after which plasmin activity was stopped by addition of aprotinin (E), whereas TAFIa-CPB-(293-401) remained at 37°C to allow inactivation by conformational instability. At various time points, aliquots were removed from the reaction mixtures, and TAFIa activity for the substrate hippuryl-Arg was measured (data are expressed as means Ϯ S.D., n ϭ 3). C and D, TAFI and TAFI-CPB-(293-333) or TAFI-CPB-(293-401), respectively, were incubated with plasmin at 37°C. Aliquots of the activation mixtures were removed at the indicated times (in minutes) and subjected to SDS-PAGE (12.5%) under reducing conditions. Protein bands were visualized by staining with Coomassie Blue, and the positions of molecular mass standards (in kilodaltons) are indicated to the left.
DISCUSSION
TAFIa is a labile enzyme that can attenuate fibrinolysis. Both the relevance and the exact nature of the instability are still unclear. However, Schneider et al. (15) showed that the TAFIa Ile 325 isoform has a longer half-life than the TAFIa Thr 325 isoform and that this results in an increased antifibrinolytic potential of the TAFIa Ile 325 isoform, suggesting that the stability of TAFIa is indeed relevant for its function.
To determine which residues in TAFIa are involved in TAFIa inactivation via intrinsic conformational instability, we replaced residues of TAFI with the corresponding residues of pancreatic CPB. The rationale behind this is that, despite conservation of many characteristics between these two homologous enzymes, pancreatic CPB activity is stable, in contrast to TAFIa activity (13) . Therefore, we hypothesized that systematic replacement of TAFI residues would result in TAFI-CPB chimeras with altered stability. As a first step, we chose to A and B, the capacity of TAFI (f), TAFI-CPB-(293-333) (OE), and TAFI-CPB-(293-401) (q) to bind to plasminogen and fibrinogen, respectively, was assessed in an enzyme-linked immunosorbent assay in which a well was coated with plasminogen or fibrinogen; TAFI was allowed to bind; and the complex was detected using an anti-TAFI antibody. The data are represented as means Ϯ S.E. of duplicates. The lines represent the fit of the results of nonlinear regression of the data to the binding equation described under "Experimental Procedures." C and D, TAFI, TAFI-CPB-(293-333), and TAFI-CPB-(293-401) were incubated with the thrombin-thrombomodulin complex. At the indicated time points (in minutes), aliquots were removed from the incubation mixtures; thrombin activity was quenched with PPACK; and binding to immobilized fibrinogen (following the same procedure as described for B) (C) and fibrinogen in solution (D) was allowed. To study the binding in solution, fibrinogen was added to the aliquots of the incubation mixtures supplemented with PPACK, and complex formation was allowed for 30 min. The complexes were then captured by an immobilized anti-fibrinogen polyclonal antibody and detected using an anti-TAFI polyclonal antibody. (10, 11, 15) and that differs substantially from pancreatic CPB. The majority of the amino acids replaced in TAFI-CPB-(293-333), residues 306 -326, are predicted by the three-dimensional TAFI model proposed by Barbosa Pereira et al. (21) to form an ␣-helix across the surface of the protein. The second chimera (TAFI-CPB-(293-401)) included the same stretch of amino acids from CPB as TAFI-CPB-(293-333), but the region was extended to the C terminus.
The mutations severely altered the characteristics of the enzymes compared with wild-type TAFI. The rate of activation of TAFIa-CPB-(293-333) was reduced 4-fold, and that of TAFI-CPB-(293-401) by 100-fold. This suggests that the C-terminal part of TAFI is involved in the activation process, proteolysis at Arg 92 . This may be explained by a disturbed interaction with the thrombin-thrombomodulin complex or by a different accessibility of the proteolytic cleavage site due to a changed orientation of the activation peptide of the chimeric proteins.
The half-life by spontaneous decay of TAFIa-CPB-(293-333) was reduced to 0.9 Ϯ 0.2 min compared with wild-type TAFIa, with a half-life of 2.9 Ϯ 0.2 min, whereas the half-life of TAFI-CPB-(293-401) was strikingly prolonged to 96 Ϯ 29 min. This showed that the C terminus of TAFIa was involved in the determination of the (in)stability of TAFIa. Moreover, it showed that our approach is suitable for identifying the molecular determinants that regulate TAFIa (in)stability.
In the concentration range tested, TAFI-CPB-(293-333) could not prolong the clot lysis time of TdP. Its short half-life is probably one of the reasons for this. It has been shown that the antifibrinolytic potential of TAFI depends on the stability and that a low antifibrinolytic potential of a particular TAFI variant cannot be overcome by increasing the concentration (22) . Furthermore, TAFI-CPB-(293-333) bound to plasminogen and fibrinogen with affinities similar to those of TAFI.
TAFI-CPB-(293-401) could attenuate fibrinolysis, but less than expected based on its stability. TAFI-CPB-(293-401) was slowly activated; but once activated, TAFIa-CPB-(293-401) was relatively stable. However, it was, in contrast with what was expected, worse than wild-type TAFIa in prolonging clot lysis time. Pre-activation of TAFI-CPB-(293-401) improved its attenuating capacity only marginally, suggesting that inactivation rather than slow activation is the reason that TAFIa-CPB-(293-401) is not a very good attenuator of fibrinolysis or, alternatively, that it is less functional toward fibrin. In a system with purified components ϳ50 nM plasmin was required to obtain a clot lysis time close to the lysis time of a plasma clot in the presence of CPI or of a TdP clot. Fifty nM is probably an underestimation of the situation in a plasma system because no plasmin inhibitor or fibrin cross-linker was added in the purified system. Using 100 nM plasmin, it was shown that plasmin was able to inactivate TAFIa-CPB-(293-401), providing a possible explanation as to why TAFIa-CPB-(293-401) could not attenuate fibrinolysis very well. This is consistent with the observation that plasmin had no influence on CPB activity at the concentrations tested and that CPB is a very good attenuator of lysis. Furthermore, the fact that plasmin could both activate TAFI-CPB-(293-401) and inactivate TAFIa-CPB-(293-401) substantiated our earlier observation that plasmin inactivates TAFIa via proteolysis (12) .
TAFI-CPB-(293-401) was shown to have a very low affinity for both plasminogen and fibrinogen, whereas TAFI-CPB-(293-333) had a similar affinity for those two proteins compared with wild-type TAFI. We could not detect binding of porcine pancreatic CPB to either plasminogen or fibrinogen, although it can prolong the lysis time. Therefore, binding to plasminogen and/or fibrinogen is not a prerequisite for the attenuation of fibrinolysis. Our findings that TAFIa-CPB-(293-401) and porcine pancreatic CPB have a very low affinity for plasminogen were in agreement with findings of Tan and Eaton (23) (7), but these three amino acids are conserved in both TAFI and pancreatic pro-CPB, suggesting that residues other than these are important for plasminogen and fibrinogen binding. Although porcine pancreatic CPB cannot bind to plasminogen or fibrinogen, it is a very good attenuator of fibrinolysis, suggesting that no binding is required for the protection of the clot against lysis. It has also been shown that CPB is, like TAFIa, able to decrease the cofactor function of fibrinogen degradation products of t-PA-mediated plasminogen activation (24, 25) . So, it is more likely that there are other reasons yet to be identified, which may include a reduced rate of activation and inactivation, why TAFI-CPB-(293-401) is, despite its stability, not a good attenuator of clot lysis.
